| Accession |
PRJCA012345 |
| Title |
Randomized, Open-Label, Phase 3 Trial of Nivolumab plus Ipilimumab or Nivolumab plus Platinum-Doublet Chemotherapy versus Platinum-Doublet Chemotherapy in Early Stage NSCLC |
| Relevance |
Medical |
| Data types |
biomaker PD-L1; Metabolic data
|
| Organisms |
Homo sapiens
|
| Description |
This phase 3 study, CA209816, will evaluate the clinical efficacy of nivolumab plus ipilimumab or nivolumab plus platinum doublet chemotherapy in operable lung cancer. Specifically, this study will compare event free survival (EFS) and compare the pathologic complete response (pCR) rate among participants with Stage IB-IIIa NSCLC treated with nivolumab plus platinum doublet chemotherapy to the EFS and pCR rates in participants treated with platinum-doublet chemotherapy. |
| Sample scope |
Multiisolate |
| Release date |
2022-10-08 |
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| Bristol-Myers Squibb (China) Investment Co., Ltd., Bristol-Myers Squibb Company
|
|
2018L02288/2018L02289
|
|
|
|
| Submitter |
Changli
Wang (wangchangli309@163.com)
|
| Organization |
Tianjin Cancer Hospital |
| Submission date |
2022-10-08 |
